Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Several vaccines have been approved for combatting the COVID-19 pandemic. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)-based vaccines, for example, those developed by Moderna and Pfizer, have shown exceptional efficacy. Evidence suggests strong protection within two weeks of vaccination. Researchers from the University of California, Irvine, investigated the immune response produced by mRNA vaccines to better understand how they compare to antibodies generated by natural severe acute respiratory syndrome coronavirus 2  (SARS-CoV-2).